Categories Tiny Gem

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

  • Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces
  • InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need
  • Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model

Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces. InMed Pharmaceuticals (NASDAQ: INM), a clinical stage company developing a pipeline of pharmaceutical drug candidates to treat several diseases with a high unmet medical need, is at the forefront of developing innovative treatments for this debilitating condition, with their flagship product INM-089 showing great promise.

AMD is the leading cause of vision loss among people aged 50 and older. It comes in two forms: dry AMD, which is more common and less severe, and wet AMD, which is rarer but more severe. The exact cause of AMD is not fully understood, but it is believed to involve a combination of genetic and environmental factors.

Results from several in vitro and in vivo studies demonstrated several pharmacological effects in the potential treatment of dry AMD. These include:

  • providing neuroprotection of photoreceptors and improving photoreceptor function
  • preserving retinal function in the back of the eye
  • improving integrity of the retinal pigment epithelium (“RPE”)
  • improve the thickness of “outer nuclear layer” (“ONL”) of the retina where photoreceptors are located (Based on widely accepted ocular research, the thickness of the outer nuclear layer is strongly correlated with photoreceptor preservation and visual acuity.)

INM-089 is also a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). CB1 and CB2 receptors are both part of the endocannabinoid system that is found throughout the human body and is responsible for many homeostatic functions. CB1 receptors are primarily located in the brain and central nervous system, while CB2 receptors are involved in modulating neuroinflammation and immune responses.

InMed’s commitment to scientific excellence is reflected in its robust pipeline of cannabinoid-based treatments. In addition to INM-089 for AMD, the company is developing therapies for other serious conditions, including dermatological and Alzheimer’s diseases. Their research and development efforts are supported by a team of experienced scientists and industry professionals dedicated to bringing new treatments to market.

As InMed continues to advance INM-089 through pre-clinical studies, the company’s commitment to innovation and patient care remains steadfast. The future looks promising for those affected by AMD, thanks to the pioneering efforts of InMed Pharmaceuticals and their dedication to developing life-changing therapies.

For more information, visit the company’s website at www.InMedPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

About TinyGems

TinyGems is a specialized communications platform with a focus on innovative small-cap and mid-cap companies with bright futures and huge potential. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, TinyGems is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, TinyGems brings its clients unparalleled recognition and brand awareness. TinyGems is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, CA
www.TinyGems.com
310.299.1717 Office
Editor@TinyGems.com

TinyGems is powered by IBN

Christian Amiscua

Share
Published by
Christian Amiscua

Recent Posts

Study Finds Link Between Head Injuries and Elevated Brain Cancer Risk

A recent study conducted at Mass General Brigham has found a potential link between head…

17 hours ago

New Study Discovers Unexpected Reason for Resistance to Cancer Immunotherapy

A joint team of researchers from the University of Texas MD Anderson Cancer Center, the…

7 days ago

Vision Marine Technologies Inc. (NASDAQ: VMAR) Expands Distribution Network, Signs Exclusive Nimbus Boats Agreement for Florida’s West Coast

The agreement is a milestone in VMAR’s strategic evolution from a specialized electric propulsion manufacturer…

1 week ago

D-Wave Quantum Inc. (NYSE: QBTS) Targets Processor Development Scalability with Advanced Cryogenic Packaging Initiative

D-Wave launches initiative to develop advanced cryogenic packaging for both gate-model and annealing quantum processors.…

1 week ago

SEGG Media Corp. (NASDAQ: SEGG): The Reinvention of a Legacy Brand for the Next Era of Fan Engagement

Lottery.com rebrands as SEGG Media Corporation (NASDAQ: SEGG, LTRYW), signaling the closing of legacy challenges…

1 week ago